Market research
PRQR ProQR Therapeutics BV
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 330M
- P/E ratio
- Not available
- Analyst target
- 8.2222
- Dividend yield
- Not available
- Beta
- 0.03
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0010872495
- Market cap
- 330M
- P/E ratio
- Not available
- Analyst target
- 8.2222
- Dividend yield
- Not available
- Beta
- 0.03
About
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PRQR discussion.
5 years, 4 months ago
ProQR Therapeutics N.V is currently in a long term uptrend where the price is trading 19.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
ProQR Therapeutics N.V's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 28.7% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.6% to $-12M since the same quarter in the previous year.
Based on the above factors, ProQR Therapeutics N.V gets an overall score of 4/5.